Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan

INTRODUCTION: Lenvatinib is approved in Japan for treating patients with all histological subtypes of unresectable thyroid cancer, including differentiated thyroid cancer (DTC), medullary thyroid cancer (MTC), and anaplastic thyroid cancer (ATC). However, safety and effectiveness data are limited in...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Shunji, Tahara, Makoto, Ito, Koichi, Tori, Masayuki, Kiyota, Naomi, Yoshida, Katsutoshi, Sakata, Yukinori, Yoshida, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444395/
https://www.ncbi.nlm.nih.gov/pubmed/32676927
http://dx.doi.org/10.1007/s12325-020-01433-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444395/
https://www.ncbi.nlm.nih.gov/pubmed/32676927
http://dx.doi.org/10.1007/s12325-020-01433-8

Ejemplares similares